- Home
- SGD vs ONCO Comparison
SGD vs ONCO Comparison
Compare SGD & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGD
- ONCO
- Stock Information
- Founded
- SGD 2021
- ONCO 2018
- Country
- SGD United States
- ONCO United States
- Employees
- SGD N/A
- ONCO N/A
- Industry
- SGD
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- SGD
- ONCO Health Care
- Exchange
- SGD Nasdaq
- ONCO Nasdaq
- Market Cap
- SGD 1.8M
- ONCO 1.8M
- IPO Year
- SGD N/A
- ONCO 2022
- Fundamental
- Price
- SGD $0.85
- ONCO $4.77
- Analyst Decision
- SGD
- ONCO
- Analyst Count
- SGD 0
- ONCO 0
- Target Price
- SGD N/A
- ONCO N/A
- AVG Volume (30 Days)
- SGD 281.8K
- ONCO 226.4K
- Earning Date
- SGD 08-22-2025
- ONCO 06-12-2025
- Dividend Yield
- SGD N/A
- ONCO N/A
- EPS Growth
- SGD N/A
- ONCO N/A
- EPS
- SGD N/A
- ONCO N/A
- Revenue
- SGD $175,906.00
- ONCO $1,925,313.00
- Revenue This Year
- SGD N/A
- ONCO N/A
- Revenue Next Year
- SGD N/A
- ONCO N/A
- P/E Ratio
- SGD N/A
- ONCO N/A
- Revenue Growth
- SGD 253.11
- ONCO 153.70
- 52 Week Low
- SGD $0.65
- ONCO $3.82
- 52 Week High
- SGD $9.98
- ONCO $1,190.00
- Technical
- Relative Strength Index (RSI)
- SGD 43.60
- ONCO 43.03
- Support Level
- SGD $0.85
- ONCO $3.92
- Resistance Level
- SGD $1.08
- ONCO $5.10
- Average True Range (ATR)
- SGD 0.10
- ONCO 0.75
- MACD
- SGD -0.01
- ONCO 0.03
- Stochastic Oscillator
- SGD 22.50
- ONCO 24.80
About SGD Safe and Green Development Corporation
Safe & Green Development Corp is a real estate development company that focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe and Green Holdings factories. The company's business model is flexible and it anticipates developing properties on its own and also through joint ventures in which it partners with third-party equity investors or other developers.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.